Invicta Diagnostic limited
NNSE:INVICTA64.70
INR
+1.55
(+2.45%)
ISIN
INE0XJ501010
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Sanket Vinod Jain
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Mumbai India
- IPO Date
- Dec 8, 2025
- Website
- pcdiagnostics.in
- Similar Companies
- Business
- Invicta Diagnostic Limited is an India-based integrated diagnostic healthcare service provider that delivers comprehensive pathology, radiology, and wellness testing solutions under the brand name PC Diagnostics. The company operates through two primary divisions: Pathology and Radiology. Its service portfolio includes routine clinical pathology, biochemistry, and endocrinology testing; hematology, clinical microbiology, immunology, and serology analysis; specialized molecular diagnostics, cytogenetics, and oncology biomarkers; advanced diagnostic imaging comprising magnetic resonance imaging (MRI), computed tomography (CT) scans, and positron emission tomography-computed tomography (PET-CT) scans; digital radiography (X-ray), ultrasonography, and color Doppler imaging; bone mineral densitometry (DEXA) and digital mammography; non-invasive cardiovascular and respiratory diagnostics, including electrocardiograms (ECG), 2D echocardiography, treadmill exercise stress testing (TMT), and pulmonary function tests (PFT); preventive and executive health checkup packages; corporate wellness and pre-employment health screenings; and home sample collection services. The company delivers its diagnostic offerings through a hub-and-spoke operational model comprising centralised processing laboratories, full-service diagnostic centres, and localized collection points. Invicta Diagnostic caters to individual outpatients, referring medical practitioners, hospitals, and corporate clients across the Mumbai Metropolitan Region (MMR) and regional urban centres in the state of Maharashtra, India, including Mumbai, Dadar, Thane, Pune, Nashik, and Shegaon. The business was originally founded in January 2021 as Invicta Diagnostic LLP, converted into a private limited company in December 2023, and reconstituted as a public limited company in July 2024. Invicta Diagnostic Limited is headquartered in Mumbai, Maharashtra, India. In recent corporate developments, Invicta Diagnostic Limited completed its initial public offering (IPO) on the NSE Emerge platform of the National Stock Exchange of India in December 2025 under the ticker INVICTA, raising approximately INR 28.12 crore through a fresh issue of equity shares. The company deployed the proceeds toward network expansion, the procurement of high-end diagnostic and radiology imaging systems—such as advanced MRI and PET-CT scanners—and debt reduction. Over the last two years, the company executed a strategic regional expansion program, growing its operational footprint across Maharashtra to 11 diagnostic centres and two centralised reference laboratories, while broadening its in-house specialized testing menu in oncology, genomics, and advanced molecular pathology.